Efanesoctocog alfa, sold under the brand name Altuviiio, is a medication used for the treatment of hemophilia A (congenital factor VIII deficiency).
Efanesoctocog alfa was approved for medical use in the United States in February 2023.
Medical uses Efanesoctocog alfa is a recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment & control of bleeding episodes; and perioperative management of bleeding.
Society and culture Legal status In April 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Altuvoct, intended for the prevention and treatment of bleeding in people with hemophilia A caused by factor VIII deficiency. The applicant for this medicinal product is Swedish Orphan Biovitrum. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. Altuvoct was approved for medical use in the European Union in June 2024.
References